97P Genomic bases of endocrine sensitivity in triple-positive early breast cancer: A translational analysis of the PerELISA trial
Gaia Griguolo(University of North Carolina at Chapel Hill), V. Guarneri(University of Padua), Grazia Maria Vernaci(University of Padua), Stefano Indraccolo(University of Padua), PierFranco Conte(University of Padua), Tomás Pascual(Breast Cancer Research Foundation), Giancarlo Bisagni, Loredana Urso(Istituto Oncologico Veneto), Patricia Galván(Vall d'Hebron Institute of Oncology), Michele Bottosso(University of Padua), Antonio Frassoldati(University of Ferrara), Maria Vittoria Dieci(Istituto Oncologico Veneto), Carlo Alberto Giorgi(Istituto Oncologico Veneto), L. Pare Brunet(Oryzon Genomics (Spain)), Federica Miglietta(University of Padua), Aleix Prat(Hospital Clínic de Barcelona), Giulia Bianchi
Cited by 0
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k